Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Acquires Microcalorimeter Instrument Firm

NEW YORK (GenomeWeb News) – GE Healthcare has acquired privately held MicroCal, a maker of microcalorimeter instruments used for studying molecular interactions in pharmaceutical, biomedical, and life science research, for an undisclosed sum, the firm said today.
MicroCal’s instruments provide detailed information on the structure, function, and binding properties of arrange of biomolecules including proteins, lipids, nucleic acids, and antibodies. According to GE Healthcare, MicroCal’s instruments are already used in over a thousand labs around the world.
The UK-based division of GE said that MicroCal’s products will complement its Biacore platform. GE Healthcare bought Biacore International for $390 million in 2006, providing the company with its first platform for protein interaction research.
GE Healthcare said that it would develop MicroCal’s facility in Northampton, Mass., into a center of excellence for microcalorimetry.
“The resources of GE Healthcare and the wider GE group will allow us to significantly widen our reach and to jointly develop new technologies, products and applications which will help scientists increase their understanding of molecular interactions,” MicroCal CEO Richard Brown said in a statement.
MicroCal was majority owned by private equity firm Riverside Partners, which had invested in the firm in 1999.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.